Skip to content

Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus

Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus: Left Ventricular Diastolic Dysfunction, Myocardial Ischemia and Peripheral Vascular Insufficient

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00298844
Enrollment
350
Registered
2006-03-03
Start date
2006-01-31
Completion date
2010-01-31
Last updated
2007-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Type 2 diabetes mellitus, Macrovascular disease, Diastolic dysfunction, Intima media thickness, Single- photon emission computed tomography (SPECT)

Brief summary

The study aim is to establish a consecutive population of newly referred type 2 diabetes mellitus patients and among these to describe the degree of macrovascular disease by evaluating left ventricular systolic and diastolic function (echocardiography), myocardial perfusion (single-photon emission computed tomography (SPECT)), the peripheral vascular perfusion (strain gauge toe blood pressure measurements and a ultrasound scan of the a. carotis communis). Further, the degree of microvascular disease will be evaluated (glomerular filtration rate assessment, fundus photography and biotesiometry). Finally the cohort will be followed the next two years to assess the prognostic value of the above-mentioned parameters

Interventions

None listed

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age: ≥ 20 years. * Fasting C-peptide \> 300 pmol/l.

Exclusion criteria

* Verified medical history of macrovascular disease (stroke, myocardiac infarct, coronary revascularisation or strain gauge toe blood pressure \< 30 mmHg). * Suspected short lifespan because of malignant disease or end-stage kidney disease. * Pregnancy or planned pregnancy during the study period. * Body weight \> 150 kg. * Physical or mental disability not enabling participation in the study.

Countries

Denmark

Contacts

Primary ContactMikael K. Poulsen, PhD student
doc_mkp@hotmail.com+45 65414365
Backup ContactJan E. Henriksen, MD, PhD
jan.erik.henriksen@ouh.fyns-amt.dk+45 65414364

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026